Segan

Quick links to important sections

Segan

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Segan

Quick Facts

Property Description
Active ingredient Selegiline hydrochloride
Form Tablet, Capsule, Transdermal patch
Pharmacological class Selective MAO-B Inhibitor
General purpose Adjunctive therapy (dopamine maintenance)
Origin Synthetic compound

Defining Segan: Classification and Composition

Segan is a prescription pharmacological agent whose therapeutic activity is derived from the active ingredient, Selegiline hydrochloride. This drug is classified as a Selective and Irreversible Monoamine Oxidase B (MAO-B) Inhibitor. The compound itself is a synthetic compound, specifically a derivative of propargylamine, and is engineered as a single active ingredient product. Segan is one of the trade names associated with this specific formulation, typically presented as an oral medication for systemic delivery. The structural classification of Selegiline is based on its specific mechanism-based targeting.

Segan's General Purpose and Role in Therapy

The general purpose of Segan is to act as an adjunctive medication to support the dopaminergic system and maintain neurochemical stability in the central nervous system. Its primary role is to help preserve the body's existing supply of dopamine by irreversibly inhibiting the MAO-B enzyme, which is responsible for breaking down this crucial neurotransmitter. Agents like Selegiline are effective in modulating the concentration of monoamine neurotransmitters in the brain. This indicates that the medication assists in sustaining the chemical signals necessary for proper brain function, specifically those related to motor control and coordination.

Forms and Delivery of Selegiline Hydrochloride

Selegiline hydrochloride is available for systemic administration in multiple dosage forms, facilitating flexible therapeutic management. These include conventional capsules and tablets, as well as an orally disintegrating tablet (ODT) and a transdermal patch. The primary routes of administration are Oral and Transdermal. These various formulations exist for administration, with the oral forms relying on pharmaceutical excipients and the patch utilizing a polymer base for continuous systemic uptake through the skin.

What side effects are possible with Segan?

Possible Side Effects and Safety Information

The following information describes the official adverse reactions and safety characteristics of Selegiline hydrochloride (Segan), based strictly on regulatory classification and official government documentation.

Adverse Reaction Categories and Frequency

Adverse reactions are classified by frequency as documented in regulatory reports. Effects are commonly listed in the Nervous System, Psychiatric, Vascular, and Gastrointestinal system-organ classes.

Classification Examples of Reactions
Very Common (ge 1/10) Fatigue, Stomatitis, Anorexia.
Common (ge 1/100 to < 1/10) Dizziness, Headache, Sleeping disorders (Insomnia), Hypotension, Nausea, Constipation, Dyskinesia.
Uncommon (ge 1/1,000 to < 1/100) Psychoses, Arrhythmias, Orthostatic hypotension, Hair loss.

Documented Serious Adverse Reactions

Official labeling highlights several serious safety concerns. These include the risk of Serotonin Syndrome when used concomitantly with certain serotonergic medications, and the potential for Hypertensive Reactions, particularly at doses where the selective MAO-B inhibition is lost. Reports of Impulse Control Disorders (such as pathological gambling and hypersexuality) and Parkinsonism Hyperpyrexia Syndrome upon abrupt discontinuation are also documented.

Population-Specific Safety Considerations

The regulatory profile includes specific notes for certain patient populations. The medication is not recommended for individuals with severe renal impairment (creatinine clearance < 30 mL/min) or severe hepatic impairment. Use is preferably avoided during pregnancy and is not recommended during breastfeeding. Older adults may be more susceptible to certain effects, such as hypotension.

Exposure-Related Safety Patterns

Certain effects are noted to be more common at specific times. For example, Orthostatic Hypotension may be more frequent at the initiation of treatment. Loss of MAO-B selectivity and subsequent risk of hypertensive reactions is associated with doses above the recommended level.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations of Segan (selegiline hydrochloride) overdose and the regulatory-mandated emergency procedures.

Overdose Scope

Key Element Regulatory Documentation Statement
Documented overdose presentations Neurological signs including severe headache, confusion, seizures, stupor, and hallucinations. Cardiovascular effects may present as severe hypertension, hypotension, or an irregular pulse. Neuromuscular signs such as muscular rigidity and lockjaw are also documented.
Physiological systems affected (as stated in label) Central Nervous System (CNS), Cardiovascular System, and Autonomic System.
Dose-related or exposure-related factors (if applicable) Doses significantly exceeding the recommended level may cause loss of MAO-B selectivity, increasing the risk for severe toxicity.
Population-specific overdose notes (if applicable) Risk for treatment-emergent hypertension and orthostatic hypotension was reported as being greater in patients 65 years or older.
Emergency-response statements (as written in official documents) Treatment is symptomatic and supportive. There is no specific antidote known. Procedures may include gastric lavage and administration of activated charcoal.
When immediate medical help is required (label-derived phrasing only) Immediate medical attention must be sought for any suspected overdose. Hospital emergency room assistance is required immediately if severe symptoms, such as severe headache, chest pain, or a fast heartbeat, occur.

Overdose Classifications (High-level)

Key Element Regulatory Documentation Statement
Severity classification (as defined in official documents) Overdose may be associated with life-threatening complications, including Serotonin Syndrome, Hypertensive Crisis, and coma.
Regulatory basis (EMA / FDA / etc.) FDA Prescribing Information, Summary of Product Characteristics (SmPC).
Overdose-context constraints (as defined in official documents) Symptoms of severe toxicity may be delayed, requiring monitoring for at least 48 hours.

Resulting Overdose Structure

Official overdose statements:

  • Immediate medical attention must be sought for any suspected overdose or onset of severe symptoms.
  • Clinical manifestations include severe CNS, neuromuscular, and cardiovascular effects.
  • Life-threatening outcomes include Serotonin Syndrome and Hypertensive Crisis.
  • There is no specific antidote known, and management is strictly supportive.
  • Continuous hospital monitoring is required for at least 48 hours due to the potential for delayed symptom onset.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the selegiline overdose profile by documenting severe, systemic manifestations and the potential for life-threatening complications. This profile mandates that immediate medical attention must be sought due to the severity and potential for symptom delay. Management is strictly supportive, as officially documented, with no specific antidote known, requiring prolonged hospital observation.

Therapeutic Uses of Segan

What Segan Treats: Main Uses and Benefits

Segan (Selegiline hydrochloride) is relevant across therapeutic domains involving certain distressing symptoms. The medication is used for managing symptoms associated with Parkinson's Disease (PD) and Major Depressive Disorder (MDD).


Managing Motor and Affective Symptoms

In the context of PD, Segan is commonly used in the symptomatic management of movement problems, including resting tremor, muscle rigidity, and bradykinesia (slowness of movement). This is often applied as an adjunctive treatment when symptoms of increased neurological or muscular activity fluctuate. For MDD, it is relevant in conditions where symptoms may intensify temporarily, and is applied in addressing symptoms related to systemic imbalance, such as anhedonia and motivational deficits.

This assists with managing symptoms that interfere with daily comfort and may help patients cope more steadily with symptom fluctuations. “It is commonly used when short-term symptomatic assistance is needed for complex, fluctuating neurological symptoms.”

Quick Fact: Relief for Fluctuating Motor Control
The medication generally supports the adjunctive management of symptoms that become more disruptive during interdose periods by assisting with easing the overall symptom load during these fluctuations.

Eligibility and Restrictions for Use

The official eligibility profile for Segan (Selegiline hydrochloride) strictly defines who is permitted to use the medicine and who is absolutely prohibited, based on authoritative regulatory labeling.

Contraindicated Populations (Must Not Use)

Use is strictly prohibited and contraindicated for several populations, including:

  • Patients with a known hypersensitivity to selegiline.
  • Those currently receiving opioid drugs (e.g., meperidine), other MAO inhibitors (e.g., linezolid), dextromethorphan, St. John's wort, or cyclobenzaprine.
  • Patients with an active peptic ulcer (for conventional oral tablets) or pheochromocytoma (for the transdermal system).

Age and Condition Restrictions

Age-Related Eligibility: Safety and efficacy have not been established in the pediatric population, and use is generally not recommended in children. Adult patients are the established population for use.

Organ and Physiological Status: Use is not recommended in cases of severe renal impairment or severe hepatic impairment.

Pregnancy and Lactation: The medication is preferable to avoid during pregnancy and is not recommended during breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Segan (Selegiline hydrochloride) interacts with various substances primarily due to its capacity as a Monoamine Oxidase (MAO) inhibitor, resulting in officially documented pharmacodynamic potentiation and pharmacokinetic modification patterns.

Contraindicated Combinations

Co-administration with several drug categories is formally contraindicated in regulatory labeling due to the risk of severe reactions like Serotonin Syndrome or Hypertensive Crisis.

Classification Examples of Prohibited Substances
Opioid Analgesics Meperidine, Tramadol
Serotonergic Drugs SSRIs, SNRIs, Dextromethorphan
Other MAO Inhibitors Linezolid, St. John’s wort
Sympathomimetics Pseudoephedrine, Ephedrine

Restrictions and Timing Rules

Regulatory documents establish mandatory washout periods. A minimum of 14 days must elapse after discontinuing Segan before initiating therapy with a contraindicated opioid or MAO inhibitor.

Exposure modification is also documented, as specific oral contraceptives may increase the bioavailability of Selegiline. The concomitant intake of alcohol should be avoided as it may potentiate the effects of CNS depressants. Patients with hepatic impairment may experience higher Selegiline blood levels, which could increase interaction relevance.

Dietary restrictions apply, particularly for tyramine-rich foods at higher oral doses, due to the risk of hypertensive reaction, though this restriction is officially relaxed for the lowest transdermal patch dose.

Mechanism of Action

The action of Segan (Selegiline) is defined by its highly specific, enzyme-based mechanism within the central nervous system, leading to sustained changes in key neurotransmitter levels.

Selective Blockade of Dopamine Metabolism

Segan operates primarily by acting as a selective and irreversible inhibitor of the enzyme Monoamine Oxidase B (MAO-B). This enzyme is chiefly responsible for the breakdown of the neurotransmitter dopamine in the brain. The drug permanently inactivates MAO-B by forming a stable covalent bond at the enzyme's active site (mechanism-based inhibition). This cascade reduces the catabolism of the dopamine pool, which results in altered physiological signaling dynamics.

Sustained Augmentation of Central Dopaminergic Tone

By inhibiting the catabolism of dopamine, the mechanism results in an increase in the concentration of dopamine available for release into the synaptic cleft. This sustained boost to the endogenous neurotransmitter system augments dopaminergic neurotransmission in the motor control centers of the brain. The duration of this physiological effect is dictated by the slow turnover and synthesis rate of new MAO-B enzyme.

Mechanism Limitations and Secondary Effects

The drug's specificity is concentration-dependent; at concentrations higher than optimal, the mechanism extends to inhibit Monoamine Oxidase A (MAO-A), leading to a broader influence on other monoamine pathways. Furthermore, Selegiline is metabolized into L-amphetamine and L-methamphetamine, which exert weak, secondary catecholaminergic effects that contribute to the final pharmacological effect.

Dosage and Administration Information

How Segan is Used: Administration Guidelines

Segan (Selegiline hydrochloride) is administered via Oral or Transdermal routes, depending on the specific dosage form. Usage guidelines specify distinct dosing schedules and administration conditions for each formulation, ensuring adherence to standardized use protocols.


Dosing and Administration Routes

Form and Route Standard Adult Dosing Frequency Special Instructions
Oral Tablet/Capsule 5 mg, twice daily (max 10 mg/day) Twice daily Take with breakfast and lunch (with food).
Oral ODT (Zelapar) Starting 1.25 mg, max 2.5 mg/day Once daily Dissolve on tongue without liquid; avoid food/liquid 5 minutes before and after.
Transdermal Patch (EMSAM) Starting 6 mg/24 hours (max 12 mg/24 hours) Once daily Apply to dry, intact skin; rotate application sites daily; avoid external heat.

Dosage Adjustments and Contextual Use

Standard administration involves specific procedural steps and dose modifications. For the conventional oral forms, the dose of concomitant levodopa/carbidopa may require a gradual reduction (e.g., 10%-30%) after initiating Selegiline. Patients with mild-to-moderate hepatic impairment using the Oral ODT form require a dose reduction, typically to 1.25 mg once daily. Furthermore, individuals using the higher dose Transdermal Patches (9 mg/24 hours and 12 mg/24 hours) are instructed to adhere to mandatory dietary restrictions concerning tyramine-rich foods, a constraint that begins on the first day of treatment. The use of Selegiline has not been established in pediatric patients under 18 years of age.

Recent Clinical Evidence

Research evidence / Overview of studies for Segan

This section provides an overview of the types of official research that have been conducted to evaluate Segan (Selegiline hydrochloride) and what those studies explored, according to regulatory and scientific sources. It is intended only to describe the available evidence, not to offer clinical advice or guidance.

Evidence for Use in Parkinson's Disease (PD)

Research examining the use of oral Segan (Selegiline) in Parkinson's disease was conducted using large-scale, long-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time in adults with early, untreated PD, as well as those with advanced PD who were already taking levodopa/carbidopa.

Studies conducted with initially untreated patients monitored the time elapsed before it became necessary for patients to begin treatment with levodopa. Research highlights changes measured during the study period, showing patterns observed in the studies where research described a measured difference in the time to meeting the pre-set criteria for starting levodopa therapy when compared to a placebo. When used as an add-on to levodopa, research examined outcomes related to systemic or functional imbalance, such as changes in the duration of the "OFF" state, which captures phases of heightened symptom activity or poor motor function.

Evidence for Use in Major Depressive Disorder (MDD)

The research base for Segan in Major Depressive Disorder (MDD) is primarily linked to the transdermal patch formulation. The evaluation was carried out through short-term (e.g., 6 to 8 weeks) and long-term (up to 52 weeks) Randomized, Double-Blind, Placebo-Controlled Trials (RCTs). These studies were relevant in trials assessing short-term or episodic symptom patterns in adult outpatients.

Research reports that the primary evidence comes from the transdermal delivery system. For the oral formulation of Selegiline, research exploring short-term symptom changes for MDD at doses selective for MAO-B inhibition has not consistently documented similar measurements or patterns in trials.

What Research Still Shows as Uncertain

Research provides insight into short-term changes, but there is limited information for long-term outcomes, particularly for the oral formulation in MDD and sustained functional benefit in PD. Evidence quality varies across studies, and the findings for MDD are specific to the transdermal system. Subgroup findings are uncertain for pediatric populations and for many specialized patient groups (e.g., those with severe renal impairment).

Key Studies & References MAO-B Inhibitors: Selectivity, Clinical Effectiveness and Potential Indications

Frequently Asked Questions (FAQ)

Common questions about Segan (FAQ)


Q: How long does it typically take for Segan to start working?

A: While the drug’s primary enzyme-inhibiting action begins rapidly within hours, the full maximum therapeutic benefit may take longer to develop. Official product information indicates that the full effect for conditions like Parkinson's disease may take a period of days or weeks to fully manifest.


Q: How long will I need to keep taking Segan?

A: The decision on the exact length of time an individual needs to take Segan is highly personalized. This clinical decision is documented by the prescriber based on the patient's specific condition and response to treatment, as defined in official guidelines.


Q: What is the maximum duration of treatment with Segan studied in clinical trials?

A: Clinical studies supporting the current official uses have been conducted for periods up to 52 weeks for certain formulations, with some long-term follow-up studies in Parkinson’s disease lasting several years. The maximum studied duration varies depending on the specific formulation and the indication.


Q: How quickly does the effect of Segan wear off after the last dose?

A: Due to its irreversible mechanism of action, the enzyme-inhibiting effect of Segan persists for an extended period after the last dose. Official regulatory texts state that it typically takes approximately one to two weeks for the enzyme activity to return to baseline levels.


Q: Is Segan listed as a controlled substance?

A: According to official documentation, the active ingredient in Segan, Selegiline hydrochloride, is generally not classified as a federally controlled substance in the United States or other major regulatory jurisdictions.


Q: Is there a generic version of Segan available?

A: The active ingredient, Selegiline hydrochloride, is available in generic formulations in the market. However, some specific brand-name dosage forms of the drug, such as the Orally Disintegrating Tablet (ODT), may only be available under their specific trade names.


Q: Why is the drug name 'Segan' sometimes linked to different conditions online?

A: Segan is officially approved for use in two distinct conditions: Parkinson's disease and Major Depressive Disorder (for the transdermal patch formulation). This official range of approved uses for different formulations explains why the drug may be mentioned across varied health contexts online.


Q: Why is the mechanism of action important for understanding Segan?

A: The drug's mechanism as a Monoamine Oxidase (MAO) inhibitor is important because it is directly related to mandatory safety rules. This mechanism dictates the necessary washout periods and strict contraindications with specific drug classes (like certain opioids and antidepressants) to prevent severe reactions.


Q: Can Segan change the results of certain lab tests?

A: Official labeling notes that the medication can sometimes interfere with the results of certain laboratory tests. This includes potential interference with assays for certain common metabolites or with drug screens for amphetamine and methamphetamine due to the drug's breakdown products.


Q: Can I crush or split the Segan tablet if it is hard to swallow?

A: The orally disintegrating tablet (ODT) is designed to dissolve whole on the tongue without liquid. For the conventional oral tablet or capsule form, official patient labeling typically describes swallowing the medication whole, unless instructions for modification are specified by the prescriber.


Q: What happens if I miss a scheduled dose of Segan?

A: Official patient instructions describe a procedure for missed doses that depends on the proximity to the next scheduled dose. This procedure may involve taking the dose late or skipping it entirely, according to the official label instructions.


Q: If I have a mild side effect from Segan, should I stop taking it?

A: Official patient guidelines describe that any changes to the treatment plan, including discontinuing the medication, are typically made under the guidance of a healthcare professional.


Q: What should I do if I notice a change in my condition after starting Segan?

A: Official patient guidelines suggest that individuals contact their healthcare provider if they experience new or worsening symptoms or signs of a serious adverse reaction. This includes symptoms of a hypertensive crisis or Serotonin Syndrome.


Q: Do I need a follow-up appointment or lab work after starting Segan?

A: Official product information on dosage adjustment and warnings suggests that regular follow-up and monitoring of key health parameters are necessary during treatment. This can include monitoring for blood pressure changes or adjusting the dose due to hepatic (liver) impairment.


Q: Are the side effects of Segan the same for everyone?

A: Official data documents the frequency of adverse reactions, classifying them as common, uncommon, or rare based on clinical trial populations. However, regulatory documents acknowledge that individual patient experience with side effects can vary greatly and may not align perfectly with the general population data.


Q: Is Segan safe for older adults?

A: Official regulatory data indicates that older adults may be more susceptible to certain effects, such as hypotension (low blood pressure), when using Segan. Regulatory information indicates that use in the geriatric population necessitates careful consideration and monitoring.


Q: Does Segan interact with common pain relievers like ibuprofen?

A: Regulatory labeling specifically lists certain pain relievers and other drugs as prohibited. While common Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen are not explicitly listed as a contraindication, it is recommended to inform your prescriber about all medications, including non-prescription pain relievers.


Q: Does Segan interfere with any common vitamin supplements?

A: Regulatory documents highlight that Segan can interact with the herbal supplement St. John's wort, which is listed as contraindicated due to the risk of Serotonin Syndrome. Official guidelines indicate that informing your physician of all supplements, vitamins, and herbal products is important for safety consideration.


Q: Can I take Segan if I have a history of heart problems?

A: Official product labeling documents the potential for cardiovascular effects, including hypotension and arrhythmias (irregular heartbeat). Regulatory information suggests that careful use and monitoring may be necessary for individuals with pre-existing cardiovascular concerns.


Q: Can Segan impact blood sugar levels?

A: Regulatory documents do not commonly list specific impacts on blood glucose (blood sugar) as a frequent or serious adverse effect. However, official documents indicate that metabolic changes are a documented risk with some medications that share a similar pharmacological class.


Q: How does Segan affect the kidney?

A: Official documentation notes that the drug is not recommended for use in patients with severe renal impairment (kidney disease). Small changes in common kidney function measures like serum BUN and creatinine have also been noted in studies.


Q: Can I take Segan if I am already taking [Specific Drug Name 2]?

A: Regulatory documents list several prohibited drug categories, emphasizing the general need to avoid co-administration with other serotonergic agents or MAO inhibitors. Reviewing your full medication list with your prescriber helps confirm that the combination is appropriate based on regulatory guidelines.


Q: Is it normal to have a slight headache when first starting Segan?

A: Official product information states that headache is a common adverse reaction, meaning it occurred in at least 1% of patients in clinical studies. Adverse effects like headache can sometimes be more noticeable when first beginning treatment.


Q: Have there been recent studies about new uses for Segan?

A: Segan is officially approved for use in Parkinson's disease and Major Depressive Disorder (for the transdermal patch formulation). Although clinical trial registries may list studies exploring other potential uses, official regulatory approval is limited to these specific indications.

How should Segan be stored and disposed of?

Storage and Disposal Requirements for Segan (Selegiline Hydrochloride)

Segan must be stored according to regulatory standards to maintain its quality and efficacy. The medication requires storage at Controlled Room Temperature (15 C to 30 C) and must be kept from freezing. It is mandatory to store the tablets in a tight, light-resistant container, away from excessive heat and moisture.

Handling and Child Safety

All forms of Segan must be secured out of the reach of children. Used transdermal patches must be safely disposed of by folding the sticky sides together. Orally Disintegrating Tablets (ODT) must be discarded three months after the protective pouch is opened.

Disposal

Unused or expired Segan should ideally be disposed of via a medicine take-back program. Disposal procedures must ensure the product does not reach sewage systems or local waterways.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Segan found in:

A-Z Index: